BTZ was also tested in combination with TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) revealing potent activity against monolayer cultures of NSCLC cells, but had marginal effects in a three-dimensional spheroid NSCLC model [90]. Here, CASC3 is linked to non-small cell lung carcinoma.